BusinessCombination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical TrialBy Nasdaq OMXNov 13, 2017, 1:31 PM UTC
BusinessPeregrine Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial Evaluating Bavituximab Treatment Combination in Patients with Newly Diagnosed GlioblastomaBy Nasdaq OMXSep 7, 2017, 12:10 PM UTC
BusinessBiothera Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Study Evaluating Combination of Imprime PGG and Merck’s KEYTRUDA in Non-Small Cell Lung CancerBy Nasdaq OMXJul 19, 2017, 2:00 PM UTC
BusinessCombination Immunotherapy with Galectin-3 Inhibitor GR-MD-02 Enhances Effects in Pre-clinical Models and Early Results of Phase 1 Clinical TrialsBy Nasdaq OMXFeb 7, 2017, 9:40 PM UTC
BusinessOncoMed Initiates Phase 1b Immuno-Oncology Combination Clinical Trial for Demcizumab and Pembrolizumab (anti-PD1)By Nasdaq OMXMar 17, 2016, 12:30 PM UTC
